Moreover, we found hypermethylation of p14ARF, RASSF1 and p16INK4A genes and cytokine signalling gene (SOCS1) significantly associated with poor overall survival of CML patients on imatinib therapy. The gene discussed is SOCS1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.